FIRM FIXED PRICENO SET ASIDE USED.
TEVA PHARMACEUTICALS USA, INC. - NEW AWARD FOR GLATIRAMER ACETATE INJECTIONS WITH TEVA PHARMACEUTICALS USA, INC. ORDERING PERIOD IS AUGUST 5, 2023 TO AUGUST 4, 2024 WITH FOUR ONE-YEAR OPTIONS.
PIID: 36E79723D0023Solicitation ID: 36E79723R0012
Signed Date: Dec 3, 2025Effective Date: Aug 5, 2023
Key Details
Description
NEW AWARD FOR GLATIRAMER ACETATE INJECTIONS WITH TEVA PHARMACEUTICALS USA, INC. ORDERING PERIOD IS AUGUST 5, 2023 TO AUGUST 4, 2024 WITH FOUR ONE-YEAR OPTIONS.
Contractor Information
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
MCKESSON CORPORATION
$1.2B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
Stay Updated
Get notified about new opportunities matching your interests.